MedTrace Logo

A Study of AK129 in Patients With Advanced Malignant Tumors

NCT05645276 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2025-03-03

No results posted yet for this study

Summary

A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors

Conditions

  • Advanced Malignant Tumors(Stage IA-IB)

Interventions

DRUG

AK129 IV infusion

AK129 is administered intravenously according to the frequency and dosage of administration at different stages.

Sponsors & Collaborators

Principal Investigators

  • Jie Wang, Doctor · Cancer Hospital Chinese Academy of Medical Science

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-02
Primary Completion
2026-02-28
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05645276 on ClinicalTrials.gov